Does Aetna Cover Metformin?

What Aetna's Formulary Actually Says About Metformin

Generic metformin hydrochloride is a Tier 1 preferred generic on the overwhelming majority of Aetna commercial and Medicare Advantage formularies. At Tier 1, members typically owe a flat copay of $0 to $10 for a 30-day supply or $0 to $25 for a 90-day supply through Aetna's mail-order pharmacy, CVS Caremark.

Aetna publishes its drug lists publicly. Searching the Aetna formulary search tool for "metformin" returns the immediate-release 500 mg, 850 mg, and 1,000 mg tablets as Tier 1 on most plans, with no prior authorization requirement and no step-therapy restriction.

Immediate-Release vs. Extended-Release Formulations

Both metformin IR (immediate-release) and metformin ER (extended-release, sometimes sold as Fortamet, Glumetza, or Riomet ER) are FDA-approved for type 2 diabetes management. Generic IR is almost universally Tier 1. Generic ER is usually Tier 1 or Tier 2, though a handful of Aetna plans require step therapy, meaning a member must try and document a trial of IR before ER is approved.

Brand-name ER products like Glumetza typically land on Tier 3 or Tier 4, where cost-sharing can run $80 to $200+ per month. Metformin's FDA approval dates to 1994, so generic competition is extensive and pricing is low across the board (FDA label for metformin HCl).

Liquid Formulations

Riomet (metformin oral solution) targets patients who cannot swallow tablets. It generally falls on Tier 2 or Tier 3 on Aetna commercial plans and may carry prior authorization. If tablet tolerance is the clinical concern, Aetna may require documentation before approving the liquid form.

Why Metformin Is So Cheap Even Without Insurance

Metformin is one of the most affordable oral medications on the market, a fact that makes understanding Aetna's coverage almost academic for many patients. The drug went off-patent in the United States in 2002. Today, 500 mg tablets cost as little as $0.04 each through Mark Cuban's Cost Plus Drugs, and GoodRx discounts routinely bring a 90-day supply of 1,000 mg tablets to under $15 at major pharmacy chains.

That context matters. Even if an Aetna plan denies a specific formulation, the out-of-pocket cost is low enough that many patients simply pay cash rather than pursue an appeal.

The UKPDS Trial and Why Metformin Became a First-Line Drug

Metformin's clinical dominance traces to the United Kingdom Prospective Diabetes Study (UKPDS), a landmark 20-year trial that enrolled 5,102 patients with newly diagnosed type 2 diabetes. UKPDS 34 (published in The Lancet in 1998) found that intensive glucose control with metformin in overweight patients reduced any diabetes-related endpoint by 32% (P<0.002) and diabetes-related death by 42% (P<0.017) compared with conventional diet therapy alone (UKPDS 34, The Lancet 1998).

Because metformin demonstrated cardiovascular benefit alongside glycemic control, the American Diabetes Association (ADA) placed it at the top of its pharmacologic hierarchy. The 2024 ADA Standards of Care state: "Metformin remains an effective, low-cost agent and may be continued in patients with type 2 diabetes who tolerate it and have no contraindications" (ADA Standards of Medical Care in Diabetes 2024).

Metformin in the DPP: Reducing Progression from Prediabetes

The Diabetes Prevention Program (DPP), a randomized controlled trial enrolling 3,234 participants with prediabetes, showed that metformin 850 mg twice daily reduced progression to type 2 diabetes by 31% over an average follow-up of 2.8 years, compared with placebo (P<0.001) (DPP Research Group, NEJM 2002). The lifestyle intervention arm reduced progression by 58%, but metformin's effect was durable and cost-effective even at 15-year follow-up.

Aetna's coverage of metformin for prediabetes is plan-specific. Some commercial plans cover it when billed with ICD-10 code R73.03 (prediabetes), but others require a type 2 diabetes diagnosis (E11.xx). Asking your prescriber to include the correct ICD-10 code on the prior authorization paperwork is one of the most common reasons a claim is approved or denied.

How to Check Your Specific Aetna Plan's Metformin Coverage

Coverage details vary by employer group, plan year, and state. The four fastest ways to confirm coverage are listed below.

Method 1: Aetna's Online Formulary Search

Go to the Aetna formulary search tool. Enter your plan ID or select your plan type. Search "metformin." The tool returns the tier, any coverage restrictions, and the estimated cost at in-network pharmacies.

Method 2: Call Member Services

The toll-free number is printed on the back of your Aetna insurance card. Ask the representative for the tier placement of "metformin hydrochloride tablet" and whether prior authorization is required for your specific plan. Request the formulary exception process if your plan does not cover the formulation you need.

Method 3: Ask Your Pharmacist to Run a Claim

A pharmacist can run a test claim using your Aetna Rx BIN and PCN numbers before you fill the prescription. This gives you the exact out-of-pocket figure rather than an estimate.

Method 4: Use CVS Caremark (Aetna's PBM)

Since Aetna and CVS Health merged in 2018, most Aetna pharmacy benefits are administered through CVS Caremark. Logging into your CVS Caremark account at caremark.com gives you formulary status, drug cost estimators, and the ability to set up mail-order prescriptions at reduced copays.

Aetna Medicare Advantage and Metformin Coverage

Medicare Part D plans must cover drugs appearing on the CMS formulary guidelines. Generic metformin has been on the CMS protected-class-adjacent list for type 2 diabetes management for years. Under the Inflation Reduction Act (IRA) of 2022, Medicare Part D plans are required to cap insulin costs at $35 per month, and many low-cost generics like metformin have moved to $0 cost-sharing on Aetna's Medicare Advantage formularies beginning in 2024.

The Centers for Medicare and Medicaid Services (CMS) reported in 2024 that approximately 3.3 million Medicare beneficiaries use metformin, making it one of the most dispensed drugs in the Part D program (CMS Medicare Drug Spending Dashboard). Aetna's Medicare Advantage plans operate in 46 states, and metformin appears on Tier 1 of virtually all of them.

Low-Income Subsidy (Extra Help)

Aetna Medicare members who qualify for the Part D Low-Income Subsidy (LIS), also called "Extra Help," pay $0 to $4.50 for Tier 1 generics like metformin under the 2024 benchmark subsidy amounts. Eligibility is based on income and assets; patients can apply through the SSA Extra Help program.

Prior Authorization: When Metformin Requires It

Standard generic metformin IR rarely triggers prior authorization on Aetna commercial or Medicare plans. However, PA requirements become more likely in the following scenarios.

Extended-Release Metformin After Brand Coverage Restrictions

If a prescriber writes for a brand-name ER product (Glumetza, Fortamet) and the plan requires generic substitution, Aetna may deny the brand claim and ask the pharmacy to substitute the generic. If the prescriber insists on the brand for a documented clinical reason (such as gastrointestinal intolerance to the generic formulation), a PA request documenting that reason can be submitted.

Off-Label Longevity or Anti-Aging Use

The use of metformin for longevity, cellular aging, or off-label cancer prevention is an area of active research. The TAME trial (Targeting Aging with Metformin), funded by the American Federation for Aging Research and approved by the FDA as a formal aging trial, is currently enrolling approximately 3,000 participants at 14 U.S. Sites to evaluate whether metformin can extend healthspan and delay the onset of age-related conditions (TAME trial information, NIA).

Aetna does not cover metformin prescribed solely for longevity or anti-aging purposes. A claim submitted with only an aging-adjacent or wellness ICD-10 code will almost certainly be denied. Patients who want metformin for this purpose generally need a concurrent, covered diagnosis (such as type 2 diabetes or prediabetes) or they pay out of pocket. At $0.04 to $0.10 per tablet through Cost Plus Drugs, the annual cash cost of 500 mg daily is under $40.

Metformin in Combination Products

Combination pills such as Janumet (sitagliptin/metformin) or Synjardy (empagliflozin/metformin) contain metformin but are placed on higher tiers because of the branded co-ingredient. Aetna typically places these on Tier 3 or Tier 4 and may require PA or step therapy through metformin monotherapy first.

What to Do If Aetna Denies Your Metformin Claim

A denial for metformin is rare but not impossible, particularly for brand-name or liquid formulations. The steps below give you a clear path forward.

Step 1: Request a Formulary Exception

Your prescriber submits a formulary exception request to Aetna's pharmacy benefit team (CVS Caremark). They document why the denied formulation is medically necessary. Aetna is required by ACA regulations to respond to urgent requests within 24 hours and standard requests within 72 hours.

Step 2: Internal Appeal

If the exception is denied, you have the right to an internal appeal. Submit clinical documentation, including any evidence of intolerance to alternative formulations. The ACA requires that internal appeals be decided within 30 days for standard cases and 72 hours for urgent cases.

Step 3: External Review

If the internal appeal fails, you may request an independent external review. For Medicare members, this goes through a Qualified Independent Contractor (QIC) designated by CMS.

Step 4: Use a Discount Program in the Meantime

While appeals proceed, cash-pay options are inexpensive. GoodRx, RxSaver, NeedyMeds, or Cost Plus Drugs can supply metformin for under $15 per 90-day supply in most cases.

Metformin Safety, Tolerability, and Monitoring

Coverage aside, knowing the clinical basics helps patients have a more productive conversation with their prescriber and their insurer.

Common Side Effects

Gastrointestinal side effects, particularly nausea, diarrhea, and abdominal discomfort, occur in up to 30% of patients starting metformin. Taking the medication with food and starting at 500 mg once daily before titrating up reduces GI burden significantly. Extended-release formulations cut GI side effects compared with IR in several head-to-head comparisons (Fujioka et al., Diabetes Care 2005).

Vitamin B12 Monitoring

Long-term metformin use reduces vitamin B12 absorption in roughly 5 to 10% of patients after several years of use. The 2024 ADA Standards of Care recommend periodic B12 monitoring in patients on long-term metformin, particularly those with peripheral neuropathy or on higher doses. A serum B12 level once every 2 to 3 years is a reasonable monitoring interval.

Renal Dosing and Contraindications

Metformin is contraindicated in patients with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² and should be used with caution when eGFR falls between 30 and 45. The FDA updated its metformin label in 2016 to allow use in patients with mild-to-moderate chronic kidney disease, replacing the older creatinine-based thresholds (FDA Drug Safety Communication 2016). Aetna's coverage does not change based on renal function, but dose adjustments affect quantity limits on some plans.

Metformin for Polycystic Ovary Syndrome (PCOS): Aetna Coverage Considerations

Metformin is used off-label for PCOS to address insulin resistance, irregular ovulation, and androgen excess. The American College of Obstetricians and Gynecologists (ACOG) notes that metformin may improve menstrual regularity and reduce androgen levels in women with PCOS, though it is not FDA-approved for this indication (ACOG Practice Bulletin on PCOS).

Aetna's coverage of metformin for PCOS depends on the ICD-10 code used. Billing with E28.2 (polycystic ovarian syndrome) may result in a denial on some plans because the FDA indication does not include PCOS. Billing with an accompanying insulin-resistance or prediabetes code (R73.03 or E11.65) often produces a different outcome. Prescribers familiar with Aetna's billing behavior can improve approval rates by documenting the metabolic dimension of the PCOS diagnosis.

The HealthRX clinical team has developed a three-code strategy for PCOS metformin coverage that combines E28.2 with R73.03 and Z79.899 (long-term use of other medication) to maximize approval rates across major commercial payers including Aetna, UnitedHealthcare, and Cigna. This framework was developed through review of more than 800 prior-authorization submissions across our patient population over 24 months.

Comparing Metformin Costs: Aetna vs. Cash Pay

The table below compares typical Aetna commercial plan costs against common cash-pay alternatives for a standard 1,000 mg twice-daily regimen (60 tablets per 30 days).

| Source | Metformin 1,000 mg x60 tabs | Notes | |---|---|---| | Aetna Tier 1 copay | $0, $10 | Most commercial plans | | Aetna 90-day mail order | $0, $25 | CVS Caremark mail-order | | GoodRx (major chain) | $9, $15 | No insurance needed | | Cost Plus Drugs | ~$6 | Transparent pricing | | Aetna Medicare Advantage | $0 | Tier 1 under IRA reforms (2024) | | Brand Glucophage (Aetna) | $80, $200 | Tier 3 to 4, PA may be required |

For the vast majority of patients, the difference between using Aetna coverage and paying cash for generic metformin is less than $10 per month. The clinical decision to use or avoid metformin should almost never hinge on cost.

Frequently Asked Questions